The WHO's PHEIC declaration for the DRC Ebola outbreak, driven by Bundibugyo virus with 10 confirmed cases and 336 suspected including 88 deaths, highlights vulnerabilities in cross-border containment that echo the 2018-2020 DRC epidemic patterns but now intersect with U.S. withdrawal from WHO. Observational surveillance data from CDC reports, lacking RCT rigor and based on small confirmed samples without control groups, show two-thirds of cases in females aged 20-39, underscoring demographic risks missed in initial coverage. This connects to broader emerging disease response failures seen in prior outbreaks, where delayed intelligence sharing amplified spread. A 2022 Lancet Infectious Diseases observational study (n=~5000 across African sites, no industry conflicts noted) documented how fragmented international cooperation extended Ebola chains by weeks, a dynamic now worsened by absent U.S. access to WHO alerts. The coverage overlooks how Bundibugyo's lack of approved vaccines or therapeutics—unlike Zaire strain countermeasures—demands rapid genomic sequencing investments. Enhanced U.S. screening at borders represents a reactive pivot, yet historical patterns from the 2014 West Africa crisis reveal that travel advisories alone fail without integrated surveillance. Overall risk remains low per CDC but the situation could escalate without restored multilateral ties.